コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 sly days 1-5), rasburicase plus allopurinol (rasburicase 0.20 mg/kg/d days 1 to 3 followed by oral al
2 sis syndrome (TLS) were randomly assigned to rasburicase (0.20 mg/kg/d intravenously days 1-5), rasbu
3 ol in hyperuricemic patients was 4 hours for rasburicase, 4 hours for rasburicase plus allopurinol, a
4 Plasma uric acid response rate was 87% with rasburicase, 78% with rasburicase plus allopurinol, and
6 evaluated safety of and compared efficacy of rasburicase alone with rasburicase followed by oral allo
7 syndrome necessitates intravenous hydration, rasburicase, and management of associated electrolyte ab
8 after the first dose, patients randomized to rasburicase compared to allopurinol achieved an 86% vers
10 compared efficacy of rasburicase alone with rasburicase followed by oral allopurinol and with allopu
11 AUC(0-96) was 128 +/- 70 mg/dL.hour for the rasburicase group and 329 +/- 129 mg/dL.hour for the all
12 ter randomized trial compared allopurinol to rasburicase in pediatric patients with leukemia or lymph
14 tage lymphoma or high tumor burden leukemia, rasburicase is a safe and effective alternative to allop
18 end, the experimental setup was tested with rasburicase (known to be very sensitive to denaturation)
19 icase (0.20 mg/kg/d intravenously days 1-5), rasburicase plus allopurinol (rasburicase 0.20 mg/kg/d d
20 nts was 4 hours for rasburicase, 4 hours for rasburicase plus allopurinol, and 27 hours for allopurin
21 onse rate was 87% with rasburicase, 78% with rasburicase plus allopurinol, and 66% with allopurinol.
23 with hyperuricemia or at high risk for TLS, rasburicase provided control of plasma uric acid more ra
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。